Market Closed -
Bombay S.E.
11:00:47 10/05/2024 BST
|
5-day change
|
1st Jan Change
|
643.4
INR
|
-0.34%
|
|
-4.15%
|
-11.40%
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
25,590
|
126,468
|
157,436
|
163,914
|
163,914
|
-
|
Enterprise Value (EV)
1 |
25,590
|
126,468
|
157,436
|
120,256
|
163,914
|
163,914
|
P/E ratio
|
16.1
x
|
34.9
x
|
34.7
x
|
29.2
x
|
49
x
|
41.5
x
|
Yield
|
-
|
0.4%
|
0.32%
|
0.36%
|
0.27%
|
0.27%
|
Capitalization / Revenue
|
-
|
12.5
x
|
11.9
x
|
8.97
x
|
15
x
|
12.4
x
|
EV / Revenue
|
-
|
12.5
x
|
11.9
x
|
8.97
x
|
15
x
|
12.4
x
|
EV / EBITDA
|
-
|
28.7
x
|
27.2
x
|
21.2
x
|
37.3
x
|
28.6
x
|
EV / FCF
|
-
|
176
x
|
61.8
x
|
72.8
x
|
-
|
-
|
FCF Yield
|
-
|
0.57%
|
1.62%
|
1.37%
|
-
|
-
|
Price to Book
|
-
|
10.7
x
|
10.3
x
|
6.93
x
|
8.08
x
|
6.92
x
|
Nbr of stocks (in thousands)
|
254,565
|
254,565
|
254,565
|
254,565
|
254,565
|
-
|
Reference price
2 |
100.5
|
496.8
|
618.4
|
643.9
|
643.9
|
643.9
|
Announcement Date
|
18/06/20
|
08/06/21
|
09/05/22
|
25/05/23
|
-
|
-
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
10,097
|
13,202
|
13,403
|
10,898
|
13,210
|
EBITDA
1 |
-
|
4,405
|
5,794
|
5,665
|
4,392
|
5,740
|
EBIT
1 |
-
|
4,088
|
6,738
|
5,652
|
4,360
|
4,900
|
Operating Margin
|
-
|
40.49%
|
51.04%
|
42.17%
|
40.01%
|
37.09%
|
Earnings before Tax (EBT)
1 |
-
|
4,139
|
6,676
|
5,597
|
4,484
|
5,270
|
Net income
1 |
-
|
3,623
|
4,538
|
4,113
|
3,342
|
3,900
|
Net margin
|
-
|
35.89%
|
34.37%
|
30.69%
|
30.66%
|
29.52%
|
EPS
2 |
6.230
|
14.23
|
17.83
|
16.16
|
13.15
|
15.50
|
Free Cash Flow
1 |
-
|
720.4
|
2,548
|
1,651
|
-
|
-
|
FCF margin
|
-
|
7.13%
|
19.3%
|
12.32%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
16.35%
|
43.98%
|
29.15%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
19.88%
|
56.15%
|
40.15%
|
-
|
-
|
Dividend per Share
2 |
-
|
2.000
|
2.000
|
2.350
|
1.750
|
1.750
|
Announcement Date
|
18/06/20
|
08/06/21
|
09/05/22
|
25/05/23
|
-
|
-
|
Fiscal Period: March |
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
---|
Net sales
1 |
2,377
|
2,749
|
2,592
|
2,638
|
3,060
|
3,916
|
3,638
|
3,388
|
2,784
|
3,538
|
3,694
|
3,431
|
3,025
|
3,045
|
EBITDA
1 |
984.9
|
1,381
|
936.9
|
1,146
|
1,218
|
1,860
|
1,570
|
1,509
|
998.8
|
1,467
|
1,691
|
1,416
|
-
|
1,208
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
740.8
|
1,136
|
831.2
|
1,051
|
969.8
|
1,601
|
916.7
|
1,075
|
720.6
|
1,077
|
1,240
|
1,044
|
913
|
906
|
Net margin
|
31.16%
|
41.33%
|
32.07%
|
39.83%
|
31.69%
|
40.88%
|
25.19%
|
31.74%
|
25.88%
|
30.45%
|
33.56%
|
30.43%
|
30.18%
|
29.75%
|
EPS
|
-
|
-
|
-
|
4.130
|
3.810
|
-
|
3.600
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/10/20
|
10/02/21
|
08/06/21
|
16/08/21
|
06/11/21
|
08/02/22
|
09/05/22
|
08/08/22
|
08/11/22
|
06/02/23
|
25/05/23
|
-
|
-
|
-
|
Fiscal Period: March |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
720
|
2,548
|
1,651
|
-
|
-
|
ROE (net income / shareholders' equity)
|
35.8%
|
33.5%
|
25.2%
|
17.7%
|
17.8%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
46.40
|
60.00
|
68.20
|
79.70
|
93.00
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
1,108
|
752
|
2,858
|
1,585
|
1,900
|
Capex / Sales
|
10.98%
|
5.7%
|
21.32%
|
14.54%
|
14.38%
|
Announcement Date
|
08/06/21
|
09/05/22
|
25/05/23
|
-
|
-
|
Last Close Price
643.9
INR Average target price
685.5
INR Spread / Average Target +6.46% Consensus |
1st Jan change
|
Capi.
|
---|
| +30.38% | 684B | | +26.51% | 568B | | -4.36% | 361B | | +19.30% | 329B | | +3.73% | 284B | | +16.70% | 240B | | +8.78% | 208B | | -7.93% | 200B | | +7.68% | 166B |
Other Pharmaceuticals
|